Clinical trial · Observational
ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Mycosis Fungoides | Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- date of diagnosis to death from any cause, up to two years
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria * Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center * Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available Exclusion Criteria * Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage * Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center * Exclude one-time consultation type of new patients.
References
Publications (1)
- DERIVEDScarisbrick JJ, Quaglino P, Whittaker S, Bagot M, Guenova E, Papadavid E, Prince HM, Sanches JA, Miyashiro DR, Servitje O, Querfeld C, Akilov O, Arumainathan A, Bennett L, Battistella M, Benstead K, Berti E, Beylot-Barry M, Busschots AM, Cowan R, Dummer R, Dunnill G, Estrach T, Evison F, Bashir A, Geskin L, Gru A, Guitart J, Herrera MC, Hodak E, Horwitz S, Jonak C, Klemke CD, Knobler R, Mckay P, Marschalko M, Massone C, Matin R, Mitteldorf C, Novoa R, Ortiz-Romero P, Pimpinelli N, Pujol RM, Ranki A, Vakeva L, Rieger KE, Stadler R, Trautinger F, Latzka J, Vermeer M, Wachsmuth R, Weatherhead S, Wehkamp U, Wobser M, Kim YH. A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification. Blood. 2025 Oct 2;146(14):1687-1692. doi: 10.1182/blood.2025029628. PMID 40663780